Suppression of biofilm related, device-associated infections by staphylococcal quorum sensing inhibitors.
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology*; D018441:Biofilms / Q000187:drug effects* / Q000254:growth & development; D055499:Catheter-Related Infections / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D002408:Catheters, Indwelling / Q000009:adverse effects; D004195:Disease Models, Animal; D024881:Drug Resistance, Bacterial; D005707:Gallic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D006601:Hexoses / Q000494:pharmacology; D006801:Humans; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development; D016459:Prosthesis-Related Infections / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D053038:Quorum Sensing / Q000187:drug effects*; D054788:Ribosome Inactivating Proteins / Q000494:pharmacology*; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D013210:Staphylococcus / Q000187:drug effects* / Q000254:growth & development; D015607:Stents / Q000009:adverse effects; D013530:Surgical Wound Infection / Q000188:drug therapy / Q000378:metabolism; D014945:Wound Healing / Q000187:drug effects
D000890:Anti-Infective Agents; D006601:Hexoses; D005707:Gallic Acid; D054788:Ribosome Inactivating Proteins; C093412:hamamelitannin